Chronic peripheral neuropathic pain is difficult to treat and side effects may limit the usefulness of a drug. While opiates have been used for neuropathic pain management, tolerance develops to their analgesic efficacy, and they cause drowsiness and constipation. Empirical observations have demonstrated the efficacy of tricyclic antidepressants in treating peripheral neuropathy (Sindrup et al., 2005) . Research has shown that this effect is produced by inhibition of the neuronal reuptake of NE and 5-HT, as well as blocking the postsynaptic α-adrenergic, H 1 -histaminergic, and muscarinic cholinergic receptors. Duloxetine is a selective 5-HT and NE reuptake inhibitor that has been approved for treatment of diabetic neuropathy. Bupropion is a weak blocker of NE and DA, but not 5-HT, reuptake (Ascher et al., 1995) but was effective in reducing neuropathic pain in patients with human immunodeficiency virus (Semenchuck et al., 2001) . The involvement of DA in analgesic mechanisms suggests that a broadened analgesic range may result from the ability to enhance dopaminergic neurotransmission, in addition to activating serotonergic and noradrenergic pathways. Thus, agents which simultaneously inhibit DA, NE, and 5-HT transporters may possess a unique analgesic profile, Bicifadine [(±)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane HCl; DOV 220,075, Figure 1 ] is being developed for the treatment neuropathic pain. It inhibits NE (IC 50 = 55 nM) and 5-HT (117 nM) reuptake, with lesser potency in blocking DA reuptake (910 nM), as determined using recombinant human transporter systems (Basile et al., 2007) . In vivo microdialysis studies in the brains of rats indicate that bicifadine increases the extracellular levels of all three This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 8, 2007 as DOI: 10.1124 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org Downloaded from neurotransmitters following oral administration of analgesic doses (Basile et al., 2007) . Bicifadine was an effective antinociceptive agent in both the early (acute) and late (tonic) phases of paw-licking in the formalin test using rats and mice, unlike duloxetine or COX inhibitors, which are active only on the late stage (Iyengar et al, 2004) . It is not an inhibitor of either COX-1 or COX-2 (Basile et al., 2007) and does not induce dependence in either rodents or primates after as much as 48 days of administration (unpublished observations). Clinically, it has been shown to be effective in the treatment of acute dental (Stern et al., 2005) and bunionectomy pain (Riff et al., 2006) ; studies in humans with diabetic neuropathy are ongoing.
A human metabolism study utilizing [ 14 C]bicifadine was conducted to support its clinical trials and registration. In addition to assaying the plasma concentrations of total drug equivalents and unchanged bicifadine, the mass balance of drug-derived radioactivity in the urine and feces was determined.
Metabolites in the plasma, urine, and feces were identified and compared with those formed in vitro and in the species used for toxicology studies (Musick et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. Eight healthy male subjects (7 Caucasian and 1 African-American) participated in the study. The mean hematocrit was 44 ± 1%. After an overnight fast, the subjects ingested the [ 14 C]bicifadine in 3 capsules with 240 ml of water. They were fed a standard lunch approximately 4 h after dosing. The subjects were confined to the study site until at least 168 h postdose, at least 90% of the administered radioactivity was recovered, or until their excreta contained non-detectable amounts of radioactivity for at least 48 h. Samples were collected for 168 h for 5 subjects and 192 h for the other 3 subjects.
Sample Collection.
Blood samples (10 ml) were collected into chilled, heparinized tubes at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 h postdose. Additional blood samples were collected at 0.5, 2, 4, and 6 h postdose for plasma metabolite profiling and identification. Before centrifugation, a 2-ml sample was saved for analysis of radioactivity in whole blood. The rest was centrifuged within 45 min of collection in a refrigerated centrifuge and the plasma was divided into two tubes. One sample was used for the determination of the plasma radioactivity concentration; the other was for analysis of concentrations of bicifadine and the lactam metabolite, M12 (DOV 255, 828) . Plasma and blood samples were stored at -70ºC. Bioanalytical Assay. The analysis of plasma samples for bicifadine and M12
(DOV 255,828) were performed using a validated liquid chromatography with tandem mass spectrometery assay as detailed in the accompanying report (Musick et al., 2007) . The only changes were that 0.5 ml of plasma was assayed and a Symbiosis Pharma System (Spark Holland, Inc., Plainsboro, NJ) was used.
The latter consisted of a Symbiosis Pharma LC system, Reliance Autosampler, and an Applied Biosystems API 4000™ tandem quadrupole MS with a heated nebulizer probe.
Pharmacokinetic Analysis. Blood and plasma concentrations of radioactivity, bicifadine, and M12 above their respective lower limit of quantitation were used for pharmacokinetic analyses using noncompartmental methods (Gibaldi and Perrier, 1982 detection. The HPLC column, solvents and gradient were the same as used for metabolite profiling. After passing through the column switcher, the column effluent was split with approximately 25% diverted to the mass spectrometer and 75% to the radiometric detector. To minimize contamination of the mass spectrometer source, the first 4.5 min of each run was diverted to waste.
Samples were scanned in the positive ion full-scan mode from 80 to 700 amu with a Q1 scan time of 0.8 sec for 52 min. The ion spray voltage was 5000 V, the source temperature was 500ºC, and the exit potential was 10 V. Nitrogen was used as the curtain, nebulizer (GS1), and turbo (GS2) gas. Product ion analyses used the same instrumentation and conditions as LC/MS with the following exceptions: enhanced product ion was used for the scan function; the ionization mode was positive turbo spray; nitrogen was used as the collision gas;
This article has not been copyedited and formatted. The final version may differ from this version. 0.15%) so that it did not contribute to the m/z ratios as determined by mass spectrometry. For consistency across studies, the metabolite numbering system is the same as that used in the in vitro and nonclinical metabolism studies Musick et al., 2007) .
The high resolution mass spectrum of the ion at the nominal m/z 135 in M9 was obtained using a Thermo LTZ/Orbitrap Fourier transform mass spectrometer (Thermo Fisher Scientific, Inc.,Waltham, MA). A solution of M9
was infused using an electrospray ionization source. The product ion spectrum was obtained at a resolution of 60,000 and using a lock mass of 218.08117 amu (protonated molecular ion of M9). The C max of bicifadine, 1780 ng/ml, was observed at 1.06 h postdose (Table 1) . Its AUC 0-t was 3373 ng·hr/ml, approximately 15% of the total drug equivalents in plasma. Both the t½ and the time to the last measurable concentration of plasma bicifadine were slightly shorter than for plasma radioactivity. CL/F was 59.1 l/h and V z /F was 125 l; based on the weight of the subjects, CL/F was 0.74 ± 0.28 l/h/kg and V z /F was 1.58 ± 0.32 l/kg. The lactam metabolite, M12, had a C max that was slightly lower than that of bicifadine and a T max that occurred later. While exposure to M12 was approximately 50% higher compared to that of bicifadine, their t½ values were similar.
RESULTS

Pharmacokinetics of
Excretion of Radioactivity. Almost the entire orally-ingested radioactivity was excreted into urine ( Figure 3) . By 24 h postdose, 87.3 ± 5.3% of the dose was recovered in the urine; another 1.5% was excreted over the next 72 h. Only 3.52% of the dose was excreted into the feces over the collection period. Overall recovery of radioactivity was 92.3 ± 5.2% (range = 88.1-104%). Two subjects have recoveries that were slightly below 90% (88.1% and 89.4%); neither had detectable amounts of radioactivity in their feces and urine from 96 h to 192 h postdose.
Metabolite Profiling. Plasma. The pooled plasma contained 4 main radioactive peaks (Figure 4) . The highest concentration of bicifadine occurred at 0.5 h, and then declined to nondetectable levels by 6 h postdose ( Table 2 ). The main metabolites identified were the acid M3, the lactam acid M9, and the lactam M12.
With the exception of M3 at 0.5 h, all of the metabolites had concentrations that were higher than bicifadine. The highest concentration of the metabolites was at 2 or 4 h, and declined by 6 h. These data are consistent with the results using the validated assay that indicated that most of the plasma radioactivity was due to metabolites rather than bicifadine. A number of smaller radioactive peaks were detected in the chromatograms with concentrations that were too low to obtain reliable mass spectra. All of them had concentrations that were ≤ 31 ng equiv/g plasma with the exception of a peak at R t 51.5 min, which had a concentration of 63.5 ng equiv/g plasma at 0.5 h.
Urine. The major urinary metabolite was the lactam acid M9; it constituted 55.6%
of the administered radioactivity ( Feces. M3 and M9 represented most of the radioactivity in feces (0.85% and 1.34% of the dose, respectively; Table 3, Figure 5 ). Two other unidentified metabolites, with R t 's of 46.0 and 50.6 min, accounted for <0.4% of the dose.
Metabolite Structure Identification. The proposed metabolic scheme for bicifadine in humans is displayed in Figure 6 . (Table   4 ). The HPLC retention times of the plasma peaks were also the same as the standards.
The high resolution mass spectrum of the ion at m/z 135 in the product ion mass spectrum of M9 was also determined. (Figure 7) , and M2 (m/z 121) (Musick et al., 2007) .
M3 (bicifadine carboxylic acid). The full scan LC/MS mass spectrum of M3 had a [M+H]
+ at m/z 204, 30 amu (+2 oxygen -2 hydrogen) higher than bicifadine ( Figure 7 ). The presence of ions at m/z 135 and 163 in the product ion mass spectrum of M3 indicated that the methyl group had been oxidized to a carboxylic acid. which of the 6 peaks was the initial 1-O-β-acyl glucuronide. and 50 min were detected in fecal extracts but reliable mass spectra could not be obtained.
M14A-F (M3 acyl glucuronides).
M31B-F (M9 acyl glucuronides
Safety. There were 28 adverse events that were either possibly or probably related to the study drug; they were all mild or moderate in severity. There were no clinically significant changes or abnormalities in the clinical laboratory evaluations, vital sign measurements, physical examinations, or 12-lead electrocardiograms in the study. The compound was overall well tolerated.
This article has not been copyedited and formatted. The final version may differ from this version. M9 and its glucuronide accounted for 64.3% of the radioactive dose in the excreta over the 192 h study period, while M3 and its glucuronide represented another 23.3% of the dose. It was not determined which of the M14 peaks was the initial 1-O-acyl-β-glucuronide, which are known to rearrange at neutral to slightly basic pH (Compernolle et al., 1987; Hasegawa et al., 1982; Janssen et al., 1982) . Monkeys and humans produced the glucuronide conjugate of M9 (M31B-F), but rats and mice did not (Musick et al., 2007) .
In conclusion, bicifadine was well absorbed by humans when administered as an oral solution. The T max of radioactivity and bicifadine was approximately 1 h. Most of the drug-derived radioactivity in plasma was due to metabolites, especially the lactam M12, the acid M3, and the lactam acid M9. Most of the radioactivity was recovered in urine in the first 24 h. M9 and its acyl glucuronide conjugate accounted for almost two-thirds of the dose; M3 and its glucuronide represented another 23% of the dose. No human-specific metabolites were identified and the compound was well tolerated by the subjects with no reported serious or severe adverse events.
This article has not been copyedited and formatted. The final version may differ from this version. individual subjects were profiled due to differing times for excretion of radioactivity. Fig. 6 . Proposed metabolic scheme of bicifadine in adult male subjects. This article has not been copyedited and formatted. The final version may differ from this version. a Percent of dose in urine determined from radiochemical profile of pooled urine from all 8 subjects. b Percent of dose in feces determined from radiochemical profile of pooled feces for each individual subject using samples that accounted for >80% of fecal radioactivity. -Indicates that the metabolite was not detected at that time period.
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